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ABSTRACT
Purpose The aim of this study was to develop novel
paclitaxel-loaded proliposome tablet formulations for pulmo-
nary drug delivery.
Method Proliposome powder formulations (i.e. F1 – F27)
were prepared employing Lactose monohydrate (LMH),
Microcrystalline cellulose (MCC) or Starch as a carbohydrate
carriers and Soya phosphatidylcholine (SPC), Hydrogenated
soya phosphatidylcholine (HSPC) or Dimyristoly phosphati-
dylcholine (DMPC) as a phospholipid. Proliposome powder
formulations were prepared in 1:5, 1:15 or 1:25 w/w lipid
phase to carrier ratio (lipid phase; comprising of phospholipid
and cholesterol in 1:1 M ratio) and Paclitaxel (PTX) was used
as model anticancer drug.
Results Based on flowability studies, out of 27 formulations;
F3, F6, and F9 formulations were selected as they exhibited an
excellent angle of repose (AOR) (17.24 ± 0.43, 16.41 ± 0.52
and 15.16 ± 0.72°), comparatively lower size of vesicles (i.e.
5.35 ± 0.76, 6.27 ± 0.59 and 5.43 ± 0.68 μm) and good com-
pressibility index (14.81 ± 0.36, 15.01 ± 0.35 and 14.56 ±
0.14) via Carr’s index. The selected formulations were re-
duced into Nano (N) vesicles via probe sonication, followed
by spray drying (SD) to get a dry powder of these formulations
as F3SDN, F6SDN and F9SDN, and gave high yield (>53%)
and exhibited poor to very poor compressibility index values via
Carr’s Index. Post tablet manufacturing, F3 tablets formula-
tion showed uniform weight uniformity (129.40 ± 3.85 mg),
good crushing strength (14.08 ± 1.95 N), precise tablet thick-
ness (2.33 ± 0.51 mm) and a short disintegration time of
14.35 ± 0.56 min, passing all quality control tests in accor-
dance with British Pharmacopeia (BP). Upon nebulization of
F3 tablets formulation, Ultrasonic nebulizer showed better
nebulization time (8.75 ± 0.86 min) and high output rate
(421.06 ± 7.19 mg/min) when compared to Vibrating mesh
nebulizer. PTX-loaded F3 tablet formulations were identified
as toxic (60% cell viability) to cancer MRC-5 SV2 cell lines
while safe to normal MRC-5 cell lines.
Conclusion Overall, in this study LMH was identified as a
superior carbohydrate carrier for proliposome tablet manu-
facturing in a 1:25 w/w lipid to carrier ratio for in-vitro nebu-
lization via Ultrasonic nebulizer.
KEY WORDS nebulizer . paclitaxel . proliposome . quality
control testing . tablets
ABBREVIATION
AOR Angle of repose
DPMC Dimyristoly phosphatidylcholine
F Formulation
FD Freeze dried
FDM Freeze dried Micro
FDN Freeze dried Nano
HSPC Hydrogenated soya phosphatidylcholine
LMH Lactose monohydrate
MCC Microcrystalline cellulose
M Micro
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N Nano
PS Probe sonication
PTX Paclitaxel
SEM Scanning electron microscope
SD Spray dried
SDM Spray dried Micro
SDN Spray dried Nano
SPC Soya phosphatidylcholine
TEM Transmission electron microscope
TSI Two Stage Impinge
PDI Polydispersity index
INTRODUCTION
The usage of Paclitaxel (PTX) as an anticancer agent in the
treatment of a plethora of cancers (e.g. lung, breast and neck)
is well documented (1). PTX appears as needle or fine white to
off-white crystalline powder with a molecular weight of
853.91 g/mol (chemical structure of PTX in supplementary
data (Fig. a)). PTX storage temperature is 0°C for short term
and− 20°C for long term in desiccator. A number of physi-
cochemical properties, like; size, size distribution, entrapment
efficiency and zeta potential are critical parameters for PTX-
loaded formulations. PTX is associated with a number of
physicochemical limitations, two significant issues include;
lower aqueous solubility and cellular permeability (2,3). A
number of approaches have been employed to overcome
these drawbacks, including the use of cyclodextrins, which
significantly improve PTX water solubility without altering
its cytostatic activity (4). A commercially available parenteral
formulation under the name of Taxol® is available on the
market, which has addressed the compounds poor solubility
by formulation with poly-oxyethylated castor oil and ethanol
in a 50:50 v/v ratio followed by 5–20 times dilution. However,
there are established side-effects associated with poly-
oxyethylated castor oil, namely, laboured breathing and hy-
persensitivity reactions (5). Thus, there is a clear need for a
biocompatible formulation, which enhances cellular perme-
ability and water solubility. Previous research has addressed
this need through formulation of PTX loaded onto albumin
nanoparticles, under the product Abraxane® (currently under
clinical trial). Whilst this has been observed to improve drug
permeation (circa 33%) when compared to Taxol®, human
albumin itself is of high monetary value, raising questions
surrounding affordability. An alternative medium or carrier
system is hence desirable to encapsulate PTX to aid delivery
(6). In comparison to human albumin, lipids are cheap and
provided possible use in animal model. Using these lipids,
liposomes can be manufactured on large scale using fluid-
bed technology in conjugation with freeze drying (7). The
average half-life of PTX followed by intravenous administra-
tion is reported to be between 3 and 50 h (8,9). However,
pulmonary administration of PTX has been reported to en-
hance drug accumulation within the lung and reduce systemic
distribution, which in turn exhibited reduced systemic toxicity
(10). Similarly, an in-vitro study demonstrated complete tu-
mour remission and reduced systemic toxicity post nebuliza-
tion of PTX delivered using solid lipid nanoparticles (11).
Likewise, transfersome/protransfersome is an another lipid-
based drug delivery system designed to suit different situations
and delivery scenarios, however unlike liposome and solid
lipid nanoparticles incorporate a surfactant as the primary
component, imbibing transfersome with elasticity in terms of
their structure enhancing delivery performance, also demon-
strated cytotoxic activity against cancer cells (12). A compari-
son between PTX liposome formulation as aerosol and the
intravenous administration of two commercial formulations
was conducted by Joshi, Shirsath (13). The study demonstrat-
ed no pulmonary toxicity following aerosol treatment with
75% more enhanced metastases inhibition, in comparison to
parenteral administration (13).
The biocompatibility and biodegradability of liposomes
(lipid vesicles) are well-established properties (14). Being struc-
turally similar to biological membranes, unlike poly-
oxyethylated castor oil, are not associated with hypersensitiv-
ity reactions (15,16). Hydrophobic compounds are commonly
entrapped within the concentric bilayers of the vesicles,
whereas hydrophilic molecules position into the central aque-
ous core (17). A number of studies have demonstrated that
PTX can be entrapped into liposomes bilayers without
PEGylation (18–22). Additionally, PTX entrapment and sta-
bility in bilayers may be affected by a number of factors (e.g.
presence of saturated and unsaturated hydrocarbon chains of
lipids, PEGylation, fusion or aggregation, and the presence or
absence of triglycerides (23)). PEGylation coating of liposomes
may also prolong retention time, reduce recognition and up-
take by phagocytic cells, offer protection from opsonin binding
in plasma (24–26), thus improving pharmacokinetic and
pharmacodynamics properties (27) (i.e. long circulating lipo-
somes) (28). As formulations, drug-loaded liposomes delivered
to the lungs via nebulization have been associated with a lower
incidence of system side-effects and improved therapeutic ef-
fect (29). Arikace® is a liposome formulation containing ami-
kacin for the treatment of cystic fibrosis via nebulization is
available on the market. The success of this formulation may
enhance the use of liposomal formulation for various lung
diseases (30).
However, a notable limitation of liposomes however is poor
stability upon storage (31–33) exhibited by aggregation or
fusion of vesicles and drug leakage from the vesicles (17,34).
The formulation of liposomes in a dry-stable form referred to
as proliposomes (which may be hydrated with water to gener-
ate liposomes) has been developed as a solution to stability
issues associated with the vesicles (35,36). Succinctly, prolipo-
somes are formed from a combination of drug and
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phospholipid (with or without cholesterol) termed the lipid
component, which is uniformly distributed over carbohydrate
carrier particles (14,37,38). It is important to recognize that
liposomes generated from proliposomes (via hydration using
water as aqueous medium) are typically micrometre in size,
with particles sized larger than 5 μm generally depositing in
the upper respiratory tract (33,39) (i.e. from mouth to tra-
chea), hence retarding drug deposition in the lower respirato-
ry area (from bronchi to bronchioles) of pulmonary system for
its pharmacological action. Therefore, size reduction is need-
ed in order to reduce particle size frommicrometre into nano-
metre range, in order to improve and enhance drug deposi-
tion in the middle to lower respiratory tract.
Whilst powder formulations enhance stability, they are as-
sociated with challenges due to their bulky nature, and risk
associated inhalation of small solid particles during large scale
manufacture (40). This may be remedied simply by formula-
tion as tablet, which retain stability yet offer economic feasi-
bility and convenience in handling and packaging (41).Widely
manufactured in the pharmaceutical industry, in addition to
an active pharmaceutical Ingredient tablets are formulated
with excipients, including diluents/fillers to achieve bulk in
the form of carbohydrates (42,43). Proliposomes hence im-
prove stability of formulation, extending the product shelf-
life significantly, and can be hydrated for aerosolization using
nebulizers for effective pulmonary drug delivery. Nebulization
is an effective technique for targeting the lungs, which provide
a large surface area for drug deposition. Additionally, the
technique offers needle free drug administration, improving
patient compliance with minimal training and can be admin-
istered to unconscious patients delivering the desired drug via
normal tidal breathing.
In the present study, proliposome dry formulations were
prepared in a large quantity when compared to traditional
liposome formulations (i.e. thin-film method) using a rotary
evaporator to deposit a thin film of lipid phase over the car-
bohydrate particles. Furthermore, to develop novel PTX-
loaded proliposome tablet from proliposome powder formu-
lations, followed by their examination and selection of better
drug delivery carrier to the pulmonary system using
nebulizers.
MATERIALS AND METHODS
Materials
Soya Phosphatidylcholine (SPC; Lipoid S-100; 94% purity),
Hydrogenated Soya Phosphatidylcholine (HSPC;
Pho s p h o l i p o n , 8 0% pu r i t y ) a nd D imy r i s t o l y
Phosphatidylcholine (DMPC; Lipoid-PC, 98% purity) were
purchased from Lipoid, Steinhausen, Switzerland. Paclitaxel
(PTX) was obtained from ChemieTek, Indianapolis, USA).
Analar grade methanol, acetonitrile, absolute ethanol deion-
ized water (DW) and milipore filter (10 kDa) were purchased
from Fisher Scientific Ltd., UK. Cholesterol and Fetal bovine
serum (FBS) was supplied by Sigma-Aldrich, UK. Lactose
Monohydrate (LMH), Microcrystalline Cellulose (MCC;
Avicel PH 12), and Starch (Starch-150) were purchased from
VWR (BDH Prolab), UK. The Vibrating mesh (Omron NE
U22) nebulizer was supplied by Omron Healthcare UK Ltd.,
UK. The Ultrasonic nebulizer was purchased from Uniclife
Healthcare LTD, UK. Dulbecco’s Modified Eagle Medium
(DMEM) with high glucose, TryplTrypLE™ Express Enzyme
(1X), with phenol red, and AlamarBlue™ cell viability reagent
were bought from Gibco, Thermofisher, UK. MRC-5
(ECACC 05090501) and MRC-5 SV2 (ECACC 84100401)
cell lines were obtained from Public Health England
(Salisbury, UK).
Preparation of PTX-Loaded Proliposome Formulation
Proliposome powders were prepared via slurry method (17,36).
Combinations of one of three different phospholipids i.e. SPC,
HSPC or DMPC and one of three different carbohydrate car-
riers i.e. LMH,MCC or Starch were employed in proliposome
formulations. SPC andHSPC are from natural source, whereas
DMPC is from synthetic source. The lipid phase (250 mg) pre-
pared, consisted of phospholipid and cholesterol in 1:1 M ratio.
Three different formulation ratios of lipid phase to carrier were
prepared i.e. 1:5, 1:15 and 1:25 (w/w). A model drug PTX was
incorporated at a 2 mol% concentration based on lipid phase.
In formulation of 1:5 w/w lipid to carrier ratio proliposomes,
1250 mg of LMH was transferred to a round bottom flask
(RBF) (100 ml). A lipid phase, comprised of SPC (166.66 mg)
and cholesterol (83.33 mg) with 2 mol% of PTX (7.34 mg) was
dissolved in 20 ml of absolute ethanol; this solution was then
poured over the LMH forming a slurry. Subsequently, the RBF
was subjected to rotary evaporation (Buchi Rotavapor R-114,
Buchi, Switzerland) in a water bath (Buchi Water bathe B-480,
Buchi, Switzerland) previously adjusted to 45°C. A negative
pressure was created by a vacuum pump (Buchi Vac V-501)
and the evaporation of organic solvent was continued with a
rotation speed of 270 RPM for 1 h. Following release of nega-
tive pressure, dry proliposome (i.e. powder form) were collected
in a dry air-tight glass bottle (100 ml) and stored at −18°C for
subsequent studies. This procedure was repeated using various
phospholipids, carbohydrate carriers and lipid phase to carrier
ratios to prepare 27 proliposome powder formulations
(Table I).
Carr’s Consolidation Index and Angle of Repose
For Carr’s consolidation index, a graduated cylinder (25 ml)
was employed (44,45). For each coarse carbohydrate carrier,
10 g of the measured powder was transferred to a cylinder
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followed by gentle tapping (2–3 repetitions) in order to level
the powder in the cylinder. The initial volume (V1) of the
powder was recorded; subsequently, the cylinder was affixed
to an automated controlled tapping tapped density tester
(Agilent technologies, USA). The height of the tapped cylinder
was set at 14 ± 2 mm, with a tapping rate of 100 ± 15 tapes/
min for 5 min. The final volume (V2) of powder in the cylinder
was recorded after 5 min period. Carr’s consolidation Index
was calculated via Eq. 1 using the values generated from this
experiment. The same experiment was repeated for all coarse
carbohydrate carriers (i.e. LMH, MCC and Starch) in addi-
tion to prepared proliposome powder formulations (i.e. F1 –
F27) (Table I).
Carr
0
s Index %ð Þ ¼ V2−V1
V2
 
 100 ð1Þ
In measuring angle of repose (AOR), a funnel was set up on a
clamp and stand, a height of circa 2–4 cm distance was ad-
justed from the end of the funnel to the table surface. The
weight of the powder (10 g) was first recorded and fed through
the funnel to form a uniform cone (46). The height of the
powder cone was then recorded along with the diameter of
the powder base. In the event of improper cone formation, the
experiment was repeated to achieve uniform symmetrical
cone formation and subsequent accurate measurement.
AOR was calculated for three carbohydrate carriers (i.e.
LMH, MCC and Starch) and proliposome powder formula-
tions (F1 – F27) with the help of following Eq. 2;
Angle of Repose ¼ tan−1 Powder height cmð Þ
Powder base cmð Þ
 
ð2Þ
The degree of powder flow in accordance with Carr’s scale
for compressibility index and AOR are exhibited in order to
show powder characteristics (Table II) (47).
Size and Zeta Potential Analysis
Liposomes were generated from proliposome powder formu-
lations via hydration using water as a dispersion medium
(30 mg/ml) followed by 1 h annealing time (i.e. conducted
above the phase transition temperature of phospholipid).
The phase transition temperature of SPC, HSPC and
DMPC are −20, 52, and 23°C, respectively. Liposome vesicle
size (also referred to as VolumeMedian Diameter; VMD) and
PDI (referred to as size distribution) analysis of liposome gen-
erated from proliposomes were conducted using laser diffrac-
tion (Malvern Mastersizer 200, Malvern Instruments, UK).
Liposome vesicle size and PDI in nanometre range
was measured via Dynamic Light Scattering (DLS) in-
strument (Zetasizer Nano; Malvern Instruments Ltd.,
UK). Zeta potential of liposome suspension was deter-
mined by Zetasizer Nanoseries (Malvern Instruments
Ltd., UK) using Laser Doppler Velocimetry (LDV) via
electrophoretic mobility of liposomes in dispersion me-
dium. Zeta potential is the term used to define the
potential difference between the conducting liquid and
Table I Proliposome Formulations (F1 – F27) Prepared Employing Three
Different Phospholipids (i.e. SPC, HSPC and DMPC), Three Different
Carbohydrate Carriers (i.e. LMH, MCC and Starch) and Three Different
Lipid Phase to Carrier Ratios (i.e. 1:5, 1:15 and 1:25 w/w). Lipid Phase was
Prepared by Using Phospholipid and Cholesterol in a 1:1 M ratio, n=3
Formulation name Carbohydrate carrier Phospholipid Lipid phase to
carrier ratio (w/w)
F1 LMH SPC 1:5
F2 LMH SPC 1:15
F3 LMH SPC 1:25
F4 LMH HSPC 1:5
F5 LMH HSPC 1:15
F6 LMH HSPC 1:25
F7 LMH DMPC 1:5
F8 LMH DMPC 1:15
F9 LMH DMPC 1:25
F10 MCC SPC 1:5
F11 MCC SPC 1:15
F12 MCC SPC 1:25
F13 MCC HSPC 1:5
F14 MCC HSPC 1:15
F15 MCC HSPC 1:25
F16 MCC DMPC 1:5
F17 MCC DMPC 1:15
F18 MCC DMPC 1:25
F19 Starch SPC 1:5
F20 Starch SPC 1:15
F21 Starch SPC 1:25
F22 Starch HSPC 1:5
F23 Starch HSPC 1:15
F24 Starch HSPC 1:25
F25 Starch DMPC 1:5
F26 Starch DMPC 1:15
F27 Starch DMPC 1:25
Table II Representing Flow Properties of Powder Using Compressibility
Index and Angle of Repose Via Carr’s Scale of Flowability (47)
Compressibility index (%) Flow character Angle of repose (degree)
1–10 Excellent 25–30
11–15 Good 31–35
16–20 Fair 36–40
21–25 Passable 41–45
26–31 Poor 46–55
32–37 Very poor 56–65
˃ 38 Very, very poor ˃ 65
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liposome vesicles immersed in the liquid dispersion (48).
Zeta potential is the overall charge liposome vesicle
acquires in a dispersion medium and it is calculated
by determining the velocity of liposome vesicles in an
electric field, also termed as electrophoretic mobility of
the vesicles. Therefore, Zetasizer was employed to mea-
sure Zeta potential of both Micro and Nano particles.
Entrapment Efficiency of PTX
Entrapment of PTX incorporated into the proliposome for-
mulations was studied using HPLC (High Performance
Liquid Chromatography). Following hydration and annealing
of the proliposome powders into liposome suspensions
(300 mg/10 ml), 1 ml of liposome suspension was diluted with
methanol to determine the total amount of drug via HPLC
(Agilent 1200 HPLC instrument, UK). For the unentrapped
component, 0.5 ml of liposome suspension was transferred to
a Millipore filter (10 kDa) (Fischer Scientific, UK) and centri-
fuged (Spectrafuge 24D, Labnet International, USA) at
15,100 g for 30 min. This allowed for the separation of the
PTX-loaded liposomes from the unentrapped portion of PTX
in suspension. The filtrate (i.e. unentrapped PTX) was diluted
with methanol and the entrapped PTX was calculated in ac-
cordance with Eq. 3. The appropriate Millipore filter was
selected on the basis of molecular weight of the target solute
(i.e. PTX= 853.91 g/mol, which is 5–10 times smaller than
the pores of Millipore filter 10 kDa), thus enabled PTX free
molecules to pass through Millipore filter as filtrate, whilst
retaining liposome vesicles in the Millipore filter due to their
large size (which are collectively a very large assembly of
countless number of phospholipid and cholesterol molecules
arranged in the lamellar phase (with entrapped paclitaxel
being associated with this assembly)). These differences
between paclitaxel and liposomes permitted the unen-
trapped paclitaxel to pass preferentially through the fil-
ters pores whilst liposomes with the entrapped paclitaxel
were retained by the filter.
Entrapment Efficiency %ð Þ
¼ Total drug loading−Unentrapped drug
Total drug loading
 
 100 ð3Þ
PTX was assayed using a mobile phase of Acetonitrile and
DW (deionized water) (80:20 v/v) with an injection volume of
5 μl and flow rate of 1.2 ml/min. The temperature was set and
maintained at 40°C with a detection wavelength of 230 nm.
The HPLC column used was ODS C-18 (150 mmX 4.6 mm)
of 5-μm column (Agilent technology, USA). A standard cali-
bration curve of PTX was constructed from 5 to 80 mg/ml.
Scanning Electron Microscopy (SEM) and Transmission
Electron Microscopy (TEM)
SEM was employed for surface morphology determination of
proliposome powder, with TEM utilized for the liposome sus-
pension. For SEM, proliposome sample powders were trans-
ferred to an aluminium stub. An air spray was employed to
remove excess powder from the stub. The samples were subse-
quently coated with gold via JFC-1200 Fine Coater (JEOL,
Tokyo, Japan) under vacuum for 2 min. Proliposome particles
were observed under SEM (Quanta 200, Czech Republic) at
20 kV and images were captured. For TEM, following the gen-
eration of liposomes from proliposome, a drop of liposome sus-
pension was transferred to a carbon coated copper grid (400
mesh) (TAAB Laboratories Equipment Ltd., UK). The sample
was negatively stained with 1% w/v phosphotungstic acid, and
then viewed and photographed using a Philips CM 120 Bio-
Twin TEM (Philips Electron Optics BV, Netherlands).
Spray Drying of Liposome Suspension Post Nano Sizing
Upon investigation of F1 – F27 formulations, few formulation
were selected on the basis of consolidation index, AOR, size,
Zeta potential and entrapment efficiency. Liposome suspen-
sions (hydrated as 300 mg/10 ml) (vesicles in Micro size) were
probe sonicated in to Nano size followed by spray drying (SD)
to obtain a dry powders of proliposome. Probe sonication
(Q125Qsonica, USA) was employed for a total of 10min with
only 7 min of sonication time (i.e. 2 min sonication followed by
1min break) at 80% of amplitude intensity. High intensity and
longer sonication time was used due to the high viscosity of
formulation caused by the high amount of dissolved carbohy-
drate carrier (1:25 w/w lipid phase to carrier ratio), which
were also reported previously in literature (49,50). Probe son-
ication was applied because of its simplicity and rapidity at
reducing the size of liposomes to the Nano range. Since tita-
nium (produce during probe sonication) has much higher den-
sity (being in the Micro size range) than Nano liposomes, centri-
fugation was conducting using bench centrifuge (Spectrafuge
24D, Labnet International, USA) for 5 min at 200 g in order
to remove titanium (i.e. heavy metal) particles.
Liposome formulations were fed into a Büchi Mini Spray
Dryer B-290 equipped with a high performance cyclone
(Büchi Laboratories, Switzerland) and a 0.7 mm nozzle. The
following conditions were maintained throughout the process,
including: an inlet temperature of 100°C (an outlet tempera-
ture of 50 ± 3°C), feed rate of 5–6 ml/min, spray flow rate of
400 L/h, with a setup of 100% aspirator. Liposome suspen-
sions were continuously stirred, and simultaneously fed into
the spray dryer in order to maintain homogeneity of the sus-
pension, during spray drying. Dry proliposome spray dried
powders were transferred from the collecting chamber to an
air-tight glass bottle (100 ml) in a desiccator for further studies.
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Following spray drying, the production yield was calculated
using the following Eq. 4 (51).
Yield %ð Þ ¼ W1
W2
 
 100 ð4Þ
Where, W1 is the final weight of formulation collected in
the collecting chamber of spray drying and W2 is the initial
weight of proliposome formulation before hydration in DW
(i.e. as a starting material).
Proliposome Tablet Manufacturing
Proliposome powders were compressed into proliposome tab-
lets using a Stylcam 2000R compaction simulator (Medelpharm,
France) fitted with a 7 mm flat punch and die set with 8.98 mm
filling height. The selected formulations were typically weighted
between 80 and 250mg. An average compression force of 10 kN
with a compression speed of 10 tablets per min was maintained
throughout the tabletting process. An ambient temperature of
17°C with relative humidity of 40% was maintained throughout
the process.
Quality Control Tests for Proliposome Tablets
Following tabletting, the selected formulations were subjected
to quality control testing. Four different quality control tests
were employed to assess these tablet in accordance with BP
(British Pharmacopeia) requirements, these were: Weight uni-
formity, crushing strength, thickness and disintegration
testing.
For the weight uniformity test, 20 tablets were randomly
selected from each formulation and individually weighed. The
mean weight of each batch of proliposome tablets was calcu-
lated in accordance with Eq. 5 and the variance of each tablet
from the mean was calculated (52).
Average weight ¼ X1þX2þX3þX5……X20
20
 
ð5Þ
For crushing strength, a tablet tester (Dr Schleuniger/
Pharmatron, USA) was employed to measure the mechanical
integrity of randomly selected 10 proliposome tablets. Crushing
strength of the proliposome tablets were measured in Newton.
Thickness of the proliposome tablets was measured using an
electronic digital calliper (Copley Scientific, UK). For this study,
20 proliposome tablets were randomly selected and the thickness
of the tablets were measured in millimetre (mm). Thickness was
assessed in accordance with BP acceptance criteria ±5%; for
tablets with a thickness < 12.55 mm or 3% for tablets with a
thickness > 12.55 mm (53).
For the disintegration test, 6 tablets were randomly selected
from each batch (PTZ Pharma test instruments, Germany).
Testing was conducted in a medium of distilled water (900 ml)
at a temperature of 37°C (54); with complete disintegration of
tablets determined as the disintegration time noted for all six
proliposome tablets in min.
Nebulization Studies Via Two Stage Impinge
A Two Stage Impinge (TSI) was employed as an in-vitro lung
model for the aerosolization of liposome suspension testing
two different nebulizer; an Omron (Vibrating mesh) nebulizer
and Ultrasonic nebulizer. The TSI is comprised of an upper
stage (Stage 1) representing the upper airway, and the lower
stage (Stage 2) representing the lower airway of the respiratory
tract. The cut-off aerodynamic diameter between the two
stages of TSI is 6.4 μm, hence particle less than this size can
deposit in the lower stage of TSI and are referred to as “re-
spirable or fine particle fraction” (55,56). The air flow rate was
adjusted to 60 L/min with previously placed 7 ml of DW in
the upper stage and 30 ml of DW in the lower stage of TSI. It
is the first study where two different nebulizers (i.e. Ultrasonic
and Vibrating mesh) were employed for highlighting various
features with the help of TSI including; nebulization and sput-
tering time, mass output, output rate as well as vesicles size
determination in various compartment of nebulizer reservoir,
upper stage and lower stage of TSI. Moreover, the usage of
TSI was implemented to differentiate between nebulizers per-
formance. The TSI is approved by British Pharmacopeia,
United State Pharmacopeia and European Pharmacopeia as
a standard model for the analysis of nebulized aerosols, thus it
was included as a measure of performance (57).
Proliposome tablets were hydrated in nebulizer reservoir
(5 ml; prepared with the set ratio of 30 mg/ml) and located in
front of TSI mouthpiece. Post nebulization; nebulization time,
sputtering time, aerosol mass output (%) aerosol output rate (mg/
min) as well as vesicles size in nebulizer reservoir, upper stage and
lower stage of TSI were determined for all selected formulations
and for both nebulizers (Ultrasonic and Omron) (“Nebulization
Performance Determination” section). Aerosol mass output (Eq.
6) and aerosol output rate (Eq. 7) were determinedwith the aid of
following equations;
Mass output %ð Þ
¼ Weight of nebulized formulation
Weight of formulation present in the nebulizer prior to nebulization
 
X100
ð6Þ
Aerosol output rate mg=minð Þ
¼ Weight of nebulized formulation
Complete nebulization time
 
ð7Þ
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Cell Viability/Cytotoxicity Test
MRC-5 cells (Medical Research Council cell strain 5)
and immortalized human lung fibroblast SV2 cells were
plated into flat-bottom, black 96-well plates at a density
of 1 × 104 cells/ml (90 μl per well) using Dulbecco’s
Modified Eagle Medium (DMEM) as a growth medium
with 10% of Foetal Bovine Serum (FBS), 1% of L-
glutamine and 1% of antibiotic-antimycotic solution.
These cells (i.e. MRC-5 and MRC5 SV2) were incubat-
ed at 37°C in a humidified atmosphere of 5% of CO2
for 24 h. After 24 h, these plates containing normal and
cancer cells were tested with 10% of F3 formulation (i.e.
PTX-free and PTX-loaded formulations for comparison;
when 30 mg of proliposome was hydrated in 3 ml of
DW), followed by a further incubation of 24 h. On day
three, 10% of Alamar Blue (AB) was added to each well
(kept at 37°C) to quantify cell viability (after 3 h of
incubation with AB, plates were allowed to cool at
room temperature). A microplate reader (Epoch,
BioTek Instruments Ltd., Swindon, UK) was used for
reading plates (fluorescence excitation at 545 nm used,
emission at 600 nm) (32). Values obtained for formula-
tion F3-treated well were compared with control wells
that were treated with DW. Control values were set at
100% and the values of formulation F3-treated wells
were normalized to the control values.
Statistical Analysis
All experiments were carried out in triplicate and the
values were expressed as mean ± standard deviation
(SD). For statistical analysis, One-way Analysis of
Variance (ANOVA) and student’s t test was performed
using SPSS software where appropriate to compare
more than two groups or two set of data respectively.
Statistically, significant differences between the two
groups were indicated as a p value less than 0.05.
RESULTS AND DISCUSSION
Morphology of Carbohydrate Carriers for Proliposome
Formulations
The surface morphology of various carbohydrate carriers i.e.
LMH, MCC and Starch were examined using scanning elec-
tron microscopy (SEM). LMH was observed to mainly consist
of small particles, uniform in size and shape, being typically
employed as a filler in the manufacture of tablets via direct
compression (58) (Fig. 1a). Upon formulation as proliposomes
powder, these particles were non-porous and with uniformly
distributed lipid phase a select advantages when compared to
other carriers processed using the slurry method (36,59)
(please check surface morphology of coarse carbohydrate car-
rier with high magnification in supplementary data (Fig. b)).
MCC as a carbohydrate carrier is comprised of both crys-
talline and amorphous regions with a round to oblong in
shape (i.e. oblong). Moreover, MCC is known to form aggre-
gates of smaller cellulose fibres (Fig. 1b) (58). This aggregation
results in a high degree of variation in particle size (Fig. 1b).
MCC particles, based on their shape and size may impact the
flowability of particles. However, MCC offers good tablet
forming and disintegration properties (58).
Upon examination, Starch particles were irregular in shape
and different in size (Fig. 1c). Starch offer sufficient disintegra-
tion properties by swelling dramatically during water uptake
(58).
Fig. 1 SEM images of coarse carbohydrate including; (a) lactose monohydrate (LMH), (b) microcrystalline cellulose (MCC) and, (c) Starch were employed for
proliposome formulations. These images are typical of three such different experiments.
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Flowability Studies of Proliposome Powder
Upon analysis, amongst the coarse carbohydrate carriers,
LMH exhibited good flowability in accordance with Carr’s
scale of flowability (14.66 ± 3.05) (p < 0.05) when compared
to the passable and fair flowability of MCC and Starch (22.53
± 0.28 and 19.30 ± 2.60) respectively (Tables II and III).
These coarse carrier values were used as a control in order
to assess the impact of the incorporation of various phos-
pholipids (i.e. SPC, HSPC and DMPC) or lipid phase
to carrier ratios (1:5, 1:15 and 1:25 w/w) to manufac-
ture PTX-loaded proliposome. Irrespective of phospho-
lipid type and lipid phase to carrier ratio, no significant
differences (p > 0.05) in flowability was observed in the
presence or absence of PTX and therefore formulations
without PTX were not included.
Upon using LMHwith all three phospholipid formulations
(F1 – F9), F3, F6 and F9 exhibited a good flowability (p < 0.05)
(14.81 ± 0.36 and 15.01 ± 0.35 and 14.56 ± 0.14); compared
excellent flowability of F1, F4 and F7 (9.19 ± 0.63, 9.50 ± 0.31
and 9.13 ± 0.43) respectively (Table III). Proliposome pow-
ders prepared from LMH as a carbohydrate carrier (F1 –
F9) for powder flowability studies, compressibility index
exhibited enhanced powder flowability for 1:5 > 1:15 > 1:25
w/w (irrespective of phospholipid type) (Table III). Similar
trends were noted for MCC and Starch-based proliposome
powder formulations, where compressibility index was low for
1:5 and higher for 1:25 formulations (F12, F15 and F18);
considered as fair flowability for 1:5 and passable for 1:25
formulations.
Superior flowability is advantageous in die filling, enhanc-
ing the uniformity in terms of tablet weight for PTX-loaded
Table III Coarse Carbohydrate Carriers (i.e. LMH, MCC and Starch) Employed to Prepare Proliposome Powder Formulations (F1 – F27) Followed by Their
Characterizations via Compressibility Index, Angle of Repose, Liposome Size, Pdi, Zeta Potential and Entrapment Efficiency. Data are Mean± SD, n=3
Formulations name Compressibility index (%) Angle of repose (°) Size (μm) PDI Zeta potential (mV) Entrapment efficiency (%)
LMH 14.66 ± 3.05 10.57 ± 1.23 N/A N/A −4.09 ± 0.52 N/A
MCC 22.53 ± 0.28 13.16 ± 1.11 N/A N/A 0.24 ± 0.80 N/A
Starch 19.29 ± 2.60 13.46 ± 1.24 N/A N/A −13.20 ± 3.42 N/A
F1 9.19 ± 0.63 20.45 ± 0.80 6.25± 0.71 4.54± 1.23 −3.55 ± 0.95 96.68± 3.68
F2 13.87 ± 0.14 19.62 ± 0.99 6.66± 0.68 3.57± 0.75 −3.61 ± 0.85 95.45± 3.16
F3 14.81 ± 0.36 17.24 ± 0.43 5.35± 0.76 3.32± 0.88 −3.10 ± 1.51 95.45± 2.78
F4 9.50 ± 0.31 20.47 ± 1.01 5.78± 0.65 3.33± 0.79 −4.52 ± 1.23 95.99± 2.92
F5 11.66 ± 1.12 18.62 ± 0.54 6.46± 0.69 4.32± 1.26 −4.83 ± 1.25 96.55± 4.68
F6 15.01 ± 0.35 16.41 ± 0.52 6.27± 0.59 2.94± 0.82 −3.74 ± 0.52 96.69± 4.78
F7 9.13 ± 0.43 23.92 ± 1.45 5.89± 0.66 3.53± 0.79 −2.74 ± 0.88 94.99± 3.77
F8 12.40 ± 0.61 19.96 ± 1.35 6.04± 0.74 2.72± 0.97 −3.38 ± 0.98 93.88± 5.69
F9 14.56 ± 0.14 15.16 ± 0.72 5.43± 0.68 2.54± 0.89 −2.49 ± 1.91 93.56± 4.78
F10 19.85 ± 0.65 23.54 ± 1.41 9.52± 0.89 3.35± 0.55 −3.42 ± 1.20 96.41± 3.88
F11 21.84 ± 0.99 21.33 ± 2.39 10.69± 1.26 3.38± 0.69 −3.09 ± 1.29 95.99± 3.92
F12 22.65 ± 0.42 19.26 ± 0.46 10.17± 1.42 2.79± 0.76 −3.18 ± 1.41 97.05± 4.75
F13 19.94 ± 0.94 24.32 ± 2.56 9.35± 0.93 2.83± 0.68 −4.67 ± 1.46 96.68± 5.55
F14 20.98 ± 1.04 21.42 ± 0.66 9.34± 1.05 4.22± 1.06 −4.65 ± 1.21 95.91± 5.70
F15 20.51 ± 2.44 19.21 ± 4.26 9.05± 1.26 3.88± 0.67 −4.77 ± 1.32 96.84± 5.48
F16 18.06 ± 2.35 21.66 ± 1.73 8.96± 0.85 2.64± 0.77 −3.99 ± 1.35 93.87± 4.56
F17 20.74 ± 2.76 21.74 ± 1.28 9.39± 1. 02 4.45± 1.16 −3.48 ± 0.91 94.08± 4.55
F18 24.06 ± 0.47 18.01 ± 0.64 8.53± 1.36 2.47± 0.77 −2.58 ± 1.39 93.27± 5.44
F19 18.36 ± 1.43 25.41 ± 1.81 9.59± 1.22 4.92± 1.76 −3.33 ± 1.04 97.01± 6.25
F20 22.32 ± 1.24 25.29 ± 2.79 10.01± 1.45 2.41± 0.98 −3.01 ± 0.71 96.91± 6.19
F21 23.67 ± 1.41 20.69 ± 2.15 12.07± 2.09 2.65± 0.65 −3.09 ± 0.85 96.73± 4.09
F22 19.24 ± 1.38 24.71 ± 1.56 9.04± 1.06 4.43± 1.16 −4.22 ± 1.14 96.46± 5.90
F23 23.83 ± 1.05 22.87 ± 1.72 10.74± 1.52 2.86± 0.72 −4.11 ± 1.12 95.65± 5.73
F24 24.95 ± 1.55 17.93 ± 0.53 7.84± 0.97 2.45± 0.91 −3.88 ± 0.91 97.12± 2.96
F25 18.77 ± 1.08 25.11 ± 0.52 10.85± 1.53 3.88± 0.76 −2.93 ± 0.96 94.19± 6.75
F26 22.66 ± 1.33 24.88 ± 2.36 12.28± 2.45 4.83± 1.46 −3.83 ± 0.97 93.88± 4.68
F27 23.89 ± 0.30 20.67 ± 2.64 11.15± 2.05 3.95± 1.01 −2.96 ± 0.95 94.77± 4.25
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proliposomes during manufacture. Higher lipid content, due
to the presence of higher phospholipid amount (i.e. 1:5 w/w)
in proliposome formulations associated with more favourable
compressibility index values (i.e. very low volume change not-
ed in the graduated cylinder prior and post tapping). This was
associated with a thicker coating of lipid phase (due to the
presence of phospholipid) on the carrier surface; this elevated
lipid concentration my reduce particle flow and subsequently
restrict tapped density. Lower lipid concentrations in prolipo-
some formulations (e.g. 1:25 w/w formulations) were associ-
ated with reduced resistance, thus particle flowability was no-
tably different. These results are in agreement with previous
research (17), where Stewart assay quantitative analysis of
phospholipid in 1:5, 1:10 and 1:15 w/w formulations (i.e.
phospholipid to carrier ratios w/w) demonstrated that phos-
pholipid concentration in 1:5 w/w formulations were more
when compared to the phospholipid concentration in 1:10
and 1:15 w/w formulations (17). Therefore, it was suggested
that higher lipid content in formulation is associated with
thicker coat, whereas lower lipid concentration with
thinner/inconsistent coat over carbohydrate carriers change
(please check supplementary data (Fig. c)) (59). Thus, lower
and higher changes in volume for 1:5 and 1:25 w/w powder
formulations were observed in a graduated cylinder.
Additionally, thicker coat of phospholipid on carbohydrate
carrier may enable proliposome powder sticking/picking to
the punches and die cavity during tabletting, responsible for
variation in tablets weight as well as tablets morphology.
Overall, it was found that proliposome powder with 1:5 w/
w ratios exhibited better flowability but due to the higher
resistance caused by phospholipid content may explain that
1:5 w/w formulation ratio are actually don’t show the real
flowability of powder. This point was further explained by
AOR studies. On comparison of all the carriers at the 1:25
w/w lipid to carrier ratio, LMH exhibited good flowability,
whereas the tested counterparts (MCC and starch) exhibited
passable flowability. The reduced lipid concentration at this
ratio, may be responsible for improving flow properties when
compared to formulations with a higher lipid concentration.
Coarse carbohydrate carriers exhibited excellent flowability
via AOR for LMH, MCC and Starch powders (Table III)
(47). When using LMH as a carrier for proliposome pow-
der formulations, excellent flowability was noted for all
prepared formulations (F1 – F9), with the lowest (p <
0.05) AOR was elicited by F3, F6 and F9 (17.24 ±
0.43°, 16.41 ± 0.52° and 15.16 ± 0.72°) formulations re-
spectively, when compared to the alternative LMH pro-
liposome formulations (Table III). LMH has also been
identified to possess higher flowability and compressibil-
ity when direct compression is used for tablet manufac-
turing (58). The excellent flowability of LMH as a carbo-
hydrate powder may be attributed to the uniform size
distribution (“Morphology of Carbohydrate Carriers for
Proliposome Formulations” section), identifying it as a
suitable carrier for proliposome formulations (17).
MCC and Starch-based proliposome formulations also
exhibited an excellent AOR with respect to Carr’s scale
(Table II) (47). Upon investigation of AOR amongst F10 –
F27, MCC-loaded formulation F18 (18.01 ± 0.64°) and
Starch-loaded formulation F24 (17.93 ± 0.53°) exhibited low-
er angle values when compared to the remaining formulations
(F10 – F27). MCC as a carbohydrate carrier is observed to be
oblong shape particles with asymmetrical shape and size dis-
tribution, which can be observed in the surface morphology
via SEM (“Morphology of Carbohydrate Carriers for
Proliposome Formulations” section). It is proposed, that as a
result of this shape, MCC particles demonstrated greater re-
sistance to powder flow, thus formulations based on these
carrier exhibited higher AOR values (60). Starch particles
were noted to be irregular and varied in size and shape (Fig.
1).
Overall, it was determined that compressibility index was
lower for 1:5 w/w formulations ratios when compared to 1:15
and 1:25 w/w (regardless of phospholipid type). This was at-
tributed to the high concentration of lipid phase (i.e. 1:5 w/w),
suggested greater resistance to powder flow during tapping
and therefore deceptive enhanced flowability was achieved.
However, AOR finding suggested that formulation with
1:25 w/w lipid phase to carrier ratio are better in terms of
flowability (i.e. low angle) and would demonstrate uniform die
filling. Therefore, for both compressibility index and AOR,
formulations with low lipid phase (1:25 w/w) may be of great-
er suitability in terms of flowability to manufacture tablets.
Characterization and Analysis of Liposome Size, PDI,
Zeta Potential and PTX Entrapment
Liposome size was measured following vesicle generation via
hydration and annealing from proliposome powders. Size of
liposomes prepared from LMH,MCC and Starch-based pro-
liposome powder ranged between 5.35 ± 0.76–12.28 ±
2.45 μm (Table III). LMH-based proliposome formulations
(F1 – F9) liposome generation were consistent (p > 0.05) in
size, ranging from 5.35 ± 0.76–6.66 ± 0.68 μm; this may be
attributed to the uniform carrier size and shape, as lipid phase
equally distributed over the LMH carrier particles
(“Morphology of Carbohydrate Carriers for Proliposome
Formulations” section) (Table III). Comparatively, a signifi-
cant difference (p < 0.05) in size was noted between LMH-
based liposomes and both MCC and Starch-based liposomes
(Table III). These results are suggestive that liposomes pre-
pared from LMH-based proliposomes are superior in terms
of consistency in size, when compared to liposomes generated
MCC and Starch-based proliposomes.Moreover, a hyperton-
ic environment outside liposome vesicles was created by the
slow dissolution of LMH (i.e. enable water movement from
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inside vesicles towards outside); that may possibly shrink lipo-
some as compared to liposomes generated from MCC or
Starch-based proliposomes (59).
Upon investigation, no significant difference (p > 0.05) was
observed with respect to PDI values between liposomes hy-
drated from LMH, MCC and Starch-based proliposome for-
mulations using Malvern Mastersizer. The minimum and
maximum values ranged between 2.41 ± 0.64–4.83 ± 1.46
(Table III). Values from size distribution exhibited a hetero
dispersed size, irrespective carrier or phospholipid type used
(Table III). This trend was mirrored in terms of Zeta potential,
with no significant difference (p > 0.05) observed for liposome
formulations (F1 – F27) via Malvern Zetasizer. Zeta potential
values ranged from −2.49 ± 1.91 to −4.83 ± 1.25 for all for-
mulations (Table III).
Liposomes were prepared via hydration from LMH, MCC
and Starch-based proliposomes formulations (F1 – F27).
Entrapment efficiency was found to range from 93.87 ± 4.56–
97.12 ± 2.96% respectively, with no significant difference noted
(p > 0.05) amongst all formulations (F1 – F27) (Table III). PTX
is hydrophobic drug and therefore embedded in bilayers of
liposomes but due to its bulkiness and asymmetric nature, its
loading in liposome is challenging. Various studies demonstrat-
ed that PTXmaximum loading in liposomes is ~ ≤ 3.3mol% of
the phospholipid component (61,62). Whereas, higher loading
of PTX in liposomes higher than this percentage may lead to
leakage after preparation or during storage (23). Therefore,
2 mol% of PTX was employed in these formulation and there-
fore have shown high drug entrapment in liposomes. Similarly,
high entrapment of PTX in liposome vesicles was also reported
by You et al. with the entrapment ranging from 90.29% –
91.65% (63). Additionally, 94% of PTX entrapment was also
demonstrated byRane and Prabhakar (64), and 70.83 ± 0.78%
– 89.26 ± 3.05% using SPC 100 (65). Higher entrapment effi-
ciency in all formulations may be attributed to the presence of
long hydrocarbon chains of the phospholipid component i.e.
SPC, HSPC and DMPC, which may be able to entrap or
accommodate higher PTX proportions in the bilayers of lip-
osomes as compared to the phospholipid with shorter hydro-
carbon chain length. Phospholipid with shorter chain length
offer low drug accumulation and drug loading capacity and
therefore higher amount of drug may present in formulation
as unentrapped part (i.e. free drug). It was also reported that
longer hydrophobic inner core can be created by the long acyl
chain to entrap PTX (66) as well as using DMPC as a phos-
pholipid (23,28,67).
Overall, liposomes generated from LMH-based prolipo-
some formulations offered the highest degree of consistency
in size (F1 – F9) when compared to proliposome formulations
based on other carriers (i.e. MCC and starch) (F10 – F27).
PDI values were consistent for all liposome formulations irre-
spective of phospholipid or carbohydrate carrier type. Zeta
potential values were low (p > 0.05) when liposome were
generated from DMPC, whereas a marginal increase was ob-
served in the negative scale for SPC and HSPC formulations
(due to the purity of phospholipid); this increase (p > 0.05) was
independent of carbohydrate carrier type. Entrapment effi-
ciency achieved was in excess of 93% for all liposome gener-
ated from proliposome formulations (please check PTX chro-
matogram in supplementary data (Fig. d)).
Formulation Selection
Post-examination of all 27 formulations (employing compress-
ibility index, AOR, size, PDI, Zeta potential and PTX entrap-
ment efficiency studies); four formulations were selected based
on superior properties based on the aforementioned parame-
ters and put forward for further investigation. With respect to
compressibility index and AOR studies, LMH formulated in
low lipid phase and high carrier ratio elicited desirable results
(i.e. F3, F6 and F9) (“Flowability Studies of Proliposome
Powder” section). Size analysis indicated that the size of lipo-
some vesicles was comparatively smaller (p > 0.05) when
LMH was employed as a carbohydrate carrier regardless of
phospholipid selection (“Characterization and Analysis of
Liposome Size, PDI, Zeta Potential and PTX Entrapment”
section). Moreover, formulation F24 also exhibited lower
vesicles size, which are closer to the size generated for LMH
formulations. PDI and Zeta potential analysis demonstrated
no significant difference (p > 0.05) for all formulations (i.e. F1
– F27) ((“Characterization and Analysis of Liposome Size,
PDI, Zeta Potential and PTX Entrapment” section). Similar
results of no significant difference (p > 0.05) between formula-
tions were found for PTX entrapment efficiency, where the
entrapment was in excess of 93% for all formulations (F1 –
F27) regardless of phospholipid type (SPC, HSPC and
DMPC) or carbohydrate carrier type (LMH, MCC and
Starch).
On the basis of above analysis and investigation, formula-
tions F3, F6, F9 and F24 were selected for further studies.
TEM of Liposomes
TEM was employed in order to determine the morphology
and architecture of formed liposomes following hydration of
LMH and Starch-based proliposome powders. Liposomes
were observed to be spherical in shape. These vesicles may
be multilamellar or possibly unilamellar liposomes (Fig. 2).
These images confirm that liposomes were successfully gener-
ated from the proliposome formulations.
Characterization of Nano Formulations Via Probe
Sonication Prior and Post Spray Drying
Amongst the 27 formulations, F3, F6, F9 and F24 were select-
ed and referred as Micro (M) formulations due to the size of
  116 Page 10 of 19 Pharm Res          (2020) 37:116 
vesicles in micrometre range (i.e. used for further studies).
These formulations were converted into Nano (N) vesicles
via probe sonicated followed by spray drying to obtain
the dry product and therefore these spray dried (SD)
formulations were denoted as spray dried Nano (SDN)
formulations.
LMH liposomes were significantly reduced (p < 0.05) to
355.41 ± 7.54, 364. 89 ± 8.75 and 349.66 ± 7.91 nm for for-
mulations F3, F6 and F9, when compared to Starch-based
liposomes 750. 84 ± 10.48 nm (i.e. F24) (Table IV). This
may be attributed to the carbohydrate carrier Starch, which
possesses swelling properties and may offer resistance to the
size reduction process (58).
The aforementioned four Nano sized liposome formula-
tions were SD following hydration, forming a dry proliposome
powder. These formulations were then referred to as F3SDN,
F6SDN, F9SDN and F24SDN respectively. Following rehy-
dration of these SDN proliposome powder formulations, size
was observed to increase (p > 0.05) to 368.94 ± 9.75, 370.61
± 13.87, 356.56 ± 14.85 and 973.82 ± 16.85 nm for F3SDN,
F6SDN, F9SDN and F24SDN (Table IV). Similarly, no sig-
nificant differences (p > 0.05) were observed in terms of PDI
(polydispersity index) values of liposomes post-probe sonica-
tion in addition to following rehydration of SD formulations.
Upon analysis, PTX entrapment was significantly de-
creased (p < 0.05) using probe sonication when compared to
Fig. 2 TEM images of liposomes
generated from (1:25 w/w lipid
phase to carrier ratio) LMH-based
proliposome containing (a) F3, (b)
F6, (c) F9 and, Starch-based proli-
posome (d) F24. These images are
typical of three such different
experiments.
Table IV Size, Polydispersity Index and Entrapment Efficiency (PTX) of Liposome Vesicles were Compared after Probe Sonication (PS) and Generation of
Liposome from Spray Dried Nano (SDN) Formulations (F3SDN, F6SDN, F9SDN and F24SDN). Spray Dried Formulations were Also Analysed for Production
Yield and Compressibility Index. Data are Mean± SD, n=3
Formulations Size (nm) Polydispersity
index
Production
yield (%)
Compressibility
index (%)
Entrapment
efficiency (%)
After
PS
After
SD
After
PS
After
SD
After
SD
After
SD
After
PS
After
SD
F3SDN 355.41± 7.54 368.94 ± 9.75 0.324 ± 0.57 0.345 ± 0.61 56.05 ± 2.75 35.42 ± 3.61 81.45 ± 5.76 73.66 ± 7.21
F6SDN 364. 89± 8.75 370.61 ± 13.87 0.297 ± 0.39 0.337 ± 0.53 56.14 ± 1.69 26.96 ± 6.91 75.26 ± 5.66 69.55 ± 6.48
F9SDN 349.66± 7.91 356.56 ± 14.85 0.342 ± 0.48 0.364 ± 0.52 53.05 ± 3.48 31.67 ± 4.85 77.13 ± 6.77 69.21 ± 5.92
F24SDN 750.
84± 10.48
973.82 ± 16.85 0.372 ± 0.64 0.384 ± 0.62 38.74 ± 1.06 46.55 ± 6.45 74.91 ± 5.71 65.88 ± 6.85
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entrapment before sonication (Tables III and IV). This de-
crease in entrapment efficiency was associated with high fre-
quency vibration/energy which reduced liposomes particle
size and hence enabled drug leakage. Similar results were
also reported in the literature, which demonstrated a
decrease in entrapment efficiency after probe sonication
(68,69) as well as extrusion (38). The reconstitution of Nano
particles from powder formulation (spray dried formulation)
has been demonstrated to further decrease entrapment (p >
0.05) (70), which may be related to the formulation lost during
spray drying process. However, no significant difference (p >
0.05) was demonstrated in the entrapment efficiency of PTX
after probe sonication and the rehydration of spray dried for-
mulation (Table IV).
The production yield of SDN proliposome powders
collected post spray drying ranged from 38.74 ± 1.06%
to 56.14 ± 2.65% for all four formulations (Table IV).
The lowest yield (p < 0.05) observed was for the F24SDN
formulat ion ( i .e . 38.74 ± 1.06%) (Starch-based
proliposome) when compared to LMH-based proliposome
(F3SDN, F6SDN and F9SDN) formulations (Table IV).
The reduced yield of Starch-based formulation may be
related again to its swelling property during hydration.
Upon spraying the high density Starch droplets/particles
may deposit and adhere to the internal walls of drying
chamber; hence a lower concentration of formulation
may dry in the air and collect in the collecting chamber
of spray drying apparatus. Moreover, it is also possible
that the inlet temperature employed, may cause insuffi-
cient droplet/particle drying within the drying chamber.
High moisture content of the resultant particles may be
a causative factor of greater adherence to the walls of
drying chamber as well as cyclone chamber, lowering pro-
duction yield (71,72).
Following spray drying, compressibility index values were
generated for all four formulations (i.e. F3SDN, F6SDN,
F9SDN and F24SDN). High compressibility index values
ranged from poor for F6SDN (26.96 ± 6.91) to very poor for both
F3SDN and F9SDN (35.42 ± 3.61 and 31.67 ± 4.85) to a very
very poor values for F24SDN (46.55 ± 6.45) (Tables II and IV).
High compressibility index values were associated with the
fluffy nature and surface phenomenon i.e. cohesiveness of
SD powders, causing sticker during powder flowability.
Interestingly, upon tapping, spray dried powders compressed
more readily than standard proliposome powders. This may
attribute to the small particle size, and improved morphology
(i.e. particles spherical shape) when compared to coarse car-
bohydrates or proliposome powders (60).
Consequently, formulation F24SDN was eliminated from
further studies of proliposome tableting and nebulization, due
to its high compressibility index values (i.e. 46.55 ± 6.45; very,
very poor) and low production yield (i.e. 38.74 ± 1.06)
(Table IV). A counterpart of this formulation, F24 was also
eliminated due to high compressibility index value (i.e. 24.95
± 1.55; passable) and large size of vesicles (i.e. 7.84 ± 0.97 μm)
(Table II). Based on percentage yield and size; F3SDN,
F6SDN and F9SDN were selected. However, these formula-
tions also exhibited compressibility index values, which may
possibly not enough to compress well due to the high coher-
ence and poor flowability properties (60). In summary, the
following formulations were further investigated for tablet
manufacture: F3, F6, F9, F3SDN, F6SDN and F9SDN.
Manufacture and Quality Control Tests of PTX-Loaded
Proliposome Tablets
Following selection of the proliposome Micro formulations
(F3, F6, F9) and SD Nano formulations (F3SDN, F6SDN
and F9SDN), these were subjected to tableting via a Stylcam
2000R compaction simulator (Medelpharm, France) (please
check proliposome tablets in supplementary data (Fig. e)).
These selected formulations have used LMH as a carbohy-
drate carrier in a 1:25 w/w lipid phase to carrier ratio.
Weight Variation Test
In accordance with BP requirements for coarse tablets, the
criteria set for uniformity of weight is that; if the weight of
tablet is greater than 80 mg and less than 250 mg, to comply
with the test; not more than two individual tablet weight
should deviate from the mean weight by more than ±7.5%.
Moreover, none of the tablets should deviate by more than
twice that percentage i.e. ±15% (52). Proliposome Micro for-
mulations i.e. F3, F6 and F9 had an average weight ranging
between 129.40 ± 3.85–159.58 ± 4.99 mg (Table V).
Similarly, the weight variation for SD Nano formulations
(F3SDN, F6SDN and F9SDN) were found to be in the range
of 90.15 ± 5.24 mg and 126.55 ± 5.06 mg (Table V).
According to the acceptance range of ±7.5%; all tablets were
within the range for F3, F6 and F9 formulations, passing a set
standard of BP (52).
Comparatively, in SD tablet formulations F3SDN, F6SDN
and F9SDN, five tablets demonstrated a deviation of ±7.5%
in weight for F3SDN. Whereas four tablets deviated from the
set standard for F6SDN and F9SDN formulations. The BP
specifies that only two tablets are allowed to pass from the
range of ±7.5% (Table V). Tablets weight variation for
F3SDN, F6SDN and F9SDN may be attributed to the low
flowability and high fluffy nature of SD powder (60). It is
noteworthy that post spray drying, the resultant powder
becomes electrostatically charged resulting in particle cohe-
sion/adhesion, thus developing a fluffy nature, compromising
smooth powder flow properties. The low level of powder flow-
ability i.e. poor to very poor was determined for post spray drying
(Table IV), which indicated SD powder to demonstrate resis-
tance to flow and with the powder thus unable to fill the die
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cavity with consistent weight of powder (i.e. already adjusted),
leading to inconsistent weight of tablets. Similar results of
electrostatic charge particles post spray drying were also
reported in the literature (73,74). Similar results were also
found for the compressibility index values for F6SDN, which
indicated very poor flowability of powder, whereas F3SDN and
F9SDN exhibited very very poor powder flow (Tables II and IV)
(47).
Thus, proliposomeMicro proliposome formulations F3, F6
and F9 passed the uniformity of weight test, whereas prolipo-
some SDN formulations F3SDN, F6SDN and F9SDN failed
the test.
Crushing Strength
ProliposomeMicro formulations F3, F6 and F9 exhibited high
crushing strength (Table V). SD Nano formulations tablets
(F3SDN, F6SDN and F9SDN) showed comparatively lower
crushing strength (p < 0.05) when compared to Micro formu-
lations tablets (F3, F6 and F9) (Table V). This difference may
be associated with physical differences between SD and coarse
LMH. Coarse LMH exhibits superior compactability as well
as good flowability due to its small uniform particle size and
shape (58). Moreover, the high cohesiveness of SD formula-
tion particles may result in poor flowability, occupying irreg-
ular spaces in the die cavity of tabletting machine, requiring a
lower force of compression when similar compression condi-
tions were used for all formulations.
Thus the lower crushing strength exhibited by tablets
formed from proliposome SD Nano formulations are more
susceptible to breakage during handling and shipping, where-
as proliposome Micro formulation tablets are stronger and
would retain integrity of a solid dosage form.
Thickness and Disintegration Time of Tablets
Similar to crushing strength, thickness of Micro formulation
tablets were higher (p < 0.05), when compared to SD N for-
mulation tablets (Table V). This difference is attributed to the
nature of SD proliposome powders (as explained earlier in
“Weight Variation Test” section and “Crushing Strength”
section), which exhibited very poor powder flowability leading
to variation in tablet weight, reflected in tablet thickness. The
reduced flowability of SD powder formulations may therefore
be responsible for irregular filling of tabletting die cavity
resulting in differences in tablet thickness.
Disintegration time also varied significantly (p < 0.05) be-
tween formulations F3, F6 and F9 (Table V). Elevated disin-
tegration times for F6 and F9 were directly related to the
uniformity of tablet weight and also reflected via crushing test.
Compression force is typically adjusted and set to apply a
specified force and distance in the die to compress powder
into tablet form.With increased mass of powder in the tablett-
ing die, a higher compression force is utilized to compress the
powder into tablets (“Weight Variation Test” section). In
terms of uniformity of weight, F6 exhibited a higher tablet
weight followed by F9 and subsequently lower weight was
elicited by F3. Overall, a higher compression force was
employed to compress F6 proliposome powder formulation
when compared to F9 and F3 respectively. Similar findings
were noted in terms of crushing strength, where an elevated
crushing force was required for F6, followed by a reduced
force F9 and a further reduced force for F3 tablets
(“Crushing Strength” section). Disintegration time for the for-
mulations mirrored the previous test trends. Disintegration
time was longest for F6 the proliposome tablets (i.e. 20.05 ±
1.02 min), followed by F9 (17.45 ± 1.24), with the lowest dis-
integration time observed for the F3 formulation tablets (i.e.
14.35 ± 0.56). Out of three Micro proliposome tablets formu-
lations (i.e. F3, F6 and F9), only F3 tablets disintegrated within
15 min, whereas F6 and F9 failed the test by longer disinte-
gration time (i.e. 4 tablets from six tablets showed disintegra-
tion time more than 15 min) (Table V). According to BP. (54)
requirements, the set standard required to pass disintegration
test is for all 6 tablets to disintegrate within 15 min. In the
event that one or two tablets do not disintegrate within
15 min, the test has to be repeated for 12 more tablets.
From this second test, out of all 18 tablets, 16 tablets should
disintegrate within 15 min in order for the test to be passed.
For proliposome SD Nano (F3SDN, F6SDN and F9SDN)
tablet formulations, the disintegration time was comparatively
shorter (p < 0.05) (10.57 ± 2.14, 14.89 ± 2.57 and 12.51 ±
1.65 min) than F3, F6 and F9 (Table V). This may be associ-
ated with the uniformity of weight and lower crushing strength
test results. It is suggested that the lower the tablet weight (via
low filling volume) combined with lower compression force
Table V PTX-Loaded Micro
Proliposome (F3, F6 and F9) and
SDN Formulations (F3SDN,
F6SDN and F9SDN) Tablet
Characterization via Uniformity of
Weight (mg), Crushing Strength
(N), Thickness (mm) and
Disintegration Time (min) in
Accordance with BP. Data are
Mean± SD, n=3
Formulations Weight uniformity (mg) Crushing strength (N) Thickness (mm) Disintegration time (min)
F3 129.40 ± 3.85 14.08 ± 1.95 2.33 ± 0.51 14.35 ± 0.56
F6 159.58 ± 4.99 25.60 ± 2.61 2.93 ± 0.56 20.05 ± 1.02
F9 142.80 ± 3.57 22.85 ± 2.65 2.43 ± 0.11 17.45 ± 1.24
F3SDN 90.15 ± 5.24 7.60 ± 1.57 1.24 ± 0.23 10.57 ± 2.14
F6SDN 126.55 ± 5.06 9.80 ± 1.24 1.96 ± 0.13 14.89 ± 2.57
F9SDN 109.16 ± 4.13 8.06 ± 1.15 1.80 ± 0.23 12.51 ± 1.65
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(for tablet manufacture) and lower crushing force (employed
to break the tablets) ultimately reduced the disintegration
time. Moreover, SD powder are typically porous and highly
hygroscopic in nature and therefore they tend to absorb water
(75,76). When tablets are manufactured from SD powder,
they enhance water absorption and thus disintegrate rapidly.
All SD proliposome powder tablets disintegrated within the
set BP standard (i.e. 15 min).
Overall, SD Nano tablet formulations F3SDN, F6SDN
and F9SDN passed the disintegration test, however these tab-
lets were fragile as indicated by crushing strength testing.
Moreover, these formulations failed the weight uniformity
test. Contrastingly, Micro formulation F3, F6 and F9 passed
the weight uniformity test and demonstrated high crushing
strength, however only F3 tablet formulation passed the dis-
integration test. From the BP tests, it was concluded that the
F3 Micro proliposome tablet formulation passed the quality
control tests and thus was studied for nebulization studies.
Nebulization Performance Determination
The performance of nebulization was determined using meas-
urements of nebulization time, sputtering time, mass output,
output rate, size and PDI of liposome suspensions via
Vibrating mesh (i.e. Omron) and Ultrasonic nebulizers.
Nebulization of PTX-Loaded Proliposome Tablets
This is the first study where only a minimal number of con-
stituents were used (i.e. phospholipid, cholesterol, drug and
carrier) to compress them into tablets when compared to con-
ventional tablets, containing a number of various excipients.
PTX-loaded proliposome formulations in solid dosage form
are more stable than traditional liposome suspensions (17).
Nebulization time of liposomes generated from F3Micro pro-
liposome tablet formulations (5 ml) was determined (77,78)
using Vibrating mesh and Ultrasonic nebulizers.
Nebulization time using Vibrating mesh (15.73 ± 1.23 min)
for F3 tablets was significantly higher (p < 0.05) when com-
pared to the nebulization time of Ultrasonic nebulizer (8.75
± 0.86 min) (Table VI). The presence of phospholipid and
carbohydrate carrier may enhance the viscosity of liposome
suspension (78,79), and this may supress the low energy of
atomisation employed by Vibrating mesh nebulizer (80).
Furthermore, the elevated nebulization time may be
associated with liposome vesicle size i.e. large vesicles may
cause blockage of mesh aperture, resulting in rupture of lip-
osomes as well as lengthen nebulization time (Table VI).
Ultrasonic nebulizer operate based on the movement of pie-
zoelectric crystals and therefore are not affected by liposome
vesicle size, consequently this apparatus offered shorter nebu-
lization time (Tables VI and VII). Shorter nebulization times
achieved by ultrasonic nebulizers when compared to
Vibrating mesh nebulizers are in accordance with the previ-
ous findings (81–83).
Similar to nebulization time, sputtering time exhibited a
significant difference (p < 0.05) for F3 formulation when
Vibrating mesh and Ultrasonic nebulizers were employed
(Table VI). Sputtering time identified for Vibrating mesh neb-
ulizer was 0.28 ± 0.06 min as compared to 1.27 ± 0.08 min
for Ultrasonic nebulizer. The viscosity of F3 tablet formula-
tion did not elevate the sputtering time for Vibrating mesh
nebulizer, this may be attributed to Omron’s Vibrating mesh;
which may took longer nebulization time but slowly pushed
most of the formulation from the nebulizer reservoir.
Whereas, nebulization in the Ultrasonic nebulizer is a result
of fragmentation of capillary waves, thus the viscosity of lipo-
some suspensions may supress the atomisation process (84).
Therefore, a low volume in the nebulizer reservoir may in-
crease the difficulty to form complete waves, lengthening the
sputtering time. These results are in agreement with the pre-
vious study conducted by Steckel and Eskandar (77).
In summary, the Ultrasonic nebulizer was identified as a
superior nebulizer for delivery of aerosol, due to its associated
short nebulization time. Whilst the sputtering time was elevat-
ed, it did not impact upon complete nebulization time (nebu-
lization plus sputtering time) i.e. an average of 10 min
(Ultrasonic nebulizer) then the complete nebulization time of
circa 16 min (Vibrating mesh nebulizer).
Mass Output and Output Rate of Liposome Suspension
Whilst of complete nebulization of formulations was achieved,
this is not a guarantee of complete (100%) mass output, as
remnants of the formulation remain in the reservoir, despite
nebulization (referred to as dead volume) (85). Upon investi-
gation, a significant difference (p < 0.05) in mass output was
identified between Vibrating mesh and Ultrasonic nebulizer
(Table VI). In spite of the longer nebulization time elicited by
the Vibrating mesh nebulizer, its mass output values were high
Table VI PTX-Loaded F3 Micro Proliposome Tablets Analysis Using Vibrating Mesh (i.e. Omron) and Ultrasonic Nebulizer for Nebulization Time (min),
Sputtering Time (min), Mass Output (%), and Output Rate (mg/min). Data are Mean± SD, n=3
Formulations & nebulization type Nebulization time (min) Sputtering time (min) Mass output (%) Output rate (mg/min)
Vibrating mesh F3 15.73 ± 1.23 0.28 ± 0.06 98.56 ± 3.75 306.72 ± 7.42
Ultrasonic F3 8.75 ± 0.86 1.27 ± 0.08 84.03 ± 2.49 421.06 ± 7.19
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98.56 ± 3.75%, when compared to the Ultrasonic nebulizer
i.e. 84.03 ± 2.49% (Table VI). High mass out via the
Vibrating mesh nebulizer was also confirmed by previous
investigators (79,86), which may be associated with the
lower residual volume in the Vibrating mesh nebulizer
(87,88) when compared to Ultrasonic nebulizers.
Output rate exhibited significant differences (p < 0.05) be-
tween Omron and Ultrasonic nebulizer, as it is time depen-
dent characterization. The output rate for Vibrating mesh
nebulizer was found to be 306.72 ± 7.42 mg/min when com-
pared to the 421.06 ± 7.19 mg/min of the Ultrasonic nebulizer
(Table VI). Liposome suspension viscosity may also affect the
slower rate of nebulization. This higher viscosity resulted in the
partial blockage of apertures of the mesh, also due to the large
size of liposome vesicles during nebulization. These phenomena
may explain the lower output rate (and longer nebuliza-
tion time) of Vibrating mesh nebulizer. Comparatively,
a shorter nebulization time was observed for the
Ultrasonic nebulizer, suggesting low impact of the sus-
pension viscosity and thus exhibiting a higher output
rate (Table VI).
Overall, the Ultrasonic nebulizer was found to be a
more appropriate nebulizer for the aerosolization of li-
posome suspensions prepared from F3 Micro prolipo-
some tablet formulations, which demonstrated good
mass output and high output rate. Contrastingly, the
Vibrating mesh nebulizer exhibited high mass output
with an elevated nebulization time, which impacted up-
on the output rate of l iposome suspension via
aerosolization.
Size and PDI Analysis Post Nebulization
Liposomes generated from Micro proliposome tablets F3 for-
mulation were delivered via Vibrating mesh and Ultrasonic
nebulizer (Table VII). Nebulizer type and TSI compartments
(including nebulizer reservoir, upper and lower stages) impact-
ed upon the measured size of vesicles using size analysis
(Table VII) (supplementary data (Fig. f and g)).
Regardless of nebulizer type, size of liposomes which
remained in the nebulizer reservoirs were significantly larger
(p < 0.05) than vesicles delivered to the TSI stages. Liposomes
nebulized to the lower stage via TSI using a Vibrating mesh
nebulizer exhibited smaller size (p < 0.05) than liposomes deliv-
ered to the upper stage of impinge (smaller liposomes were
incorporated in smaller aerosol droplets) and when compared
to vesicles which remained in the nebulizer reservoir
(Table VII). These results were analogous to the size of lip-
osomes obtained by the Ultrasonic nebulizer (Table VII).
This “size fractionation” of liposomes amongst various com-
partments of the TSI was also reported when liposomes were
delivered via Ultrasonic nebulizer (89), and Vibrating mesh
nebulizers (79,90). For both Vibrating mesh and Ultrasonic
nebulizers, smaller sized liposomes (than the original liposome
vesicles in suspension) were deposited in the lower stage of the
TSI (Tables II and VII). Particle size less than 5 μm are con-
sidered as respirable fraction, indicating their deposition in the
lower respiratory tract (33). PTX-loaded F3Micro proliposome
tablet formulations (Table VII), where were reduced by the
shear force of piezoelectric crystal employed by both
Vibrating mesh and Ultrasonic nebulizers. Piezoelectric crystal
Table VII Nebulization of PTX-Loaded F3 Micro Proliposome Tablet Formulation for Size Analysis Employing TSI in Various Compartments (i.e. Nebulizer
Reservoir, Upper Stage and Lower Stage). Data are Mean± SD, n=3
Formulations & nebulization type Nebulizer reservoir (Size; μm) Upper stage (Size; μm) Lower stage (Size; μm)
Vibrating mesh F3 6.86 ± 0.24 3.79 ± 0.16 2.21 ± 0.12
Ultrasonic F3 5.42 ± 0.55 4.12 ± 0.25 2.36 ± 0.25
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in the Vibrating mesh nebulizer is attached to the transducer
horn, which transmit vibrations to the perforated plate (contain-
ing 6000 tapered holes with an internal diameter of each hole of
3 μm). Liposome formulations were passed through perforated
plate to generate aerosols, which automatically reduce particle
size. Whereas, Ultrasonic nebulizer utilize baffle in addition to
high frequency vibration by piezoelectric crystal, hence reduce
particle size for aerosolization. Similar findings were also
reported in various studies (78,91,92). Therefore, these nebu-
lizer generate aerosols with a smaller particles and hence en-
abled their deposition in the upper and lower stages of TSI.
Overall, significant differences in terms of size was ob-
served for liposomes present in different compartments post
nebulization. This difference in size was insignificant in terms
of nebulizer type.
Cell Viability/Cytotoxicity Studies
In order to find a rapid and simple cell viability study, cytotox-
icity of PTX-loaded in proliposome tablets formulation (i.e. F3)
against normal MRC-5 and cancerous MRC-5 SV2 cell lines
was determined using Alamar Blue assay. The effect of F3
formulation on the viability of MRC-5 and MRC-5 SV2 cells
was designed for 24 h (Fig. 3). Employing PTX-free formula-
tions, the cell viability of both cell lines was unaffected
(p> 0.05), indicating that the manufacture process and formu-
lations parameters of proliposomes (i.e. PTX-free F3 onMRC-
5 and MRC-5 SV2) had no effect on the cytotoxicity.
Correspondingly, PTX-loaded F3 tablet formulation was safe
in MRC-5 cell lines (Fig. 3) (with a PTX concentration of 10%
formulations). On the other hand, using similar concentration
of PTX was noted to be significantly (p< 0.05) toxic to MRC-5
SV2 cell line, exhibiting 58% cell viability. Thus, it was found
that PTX-loaded F3 tablets formulation was safe in normal cell
lines but significantly toxic to cancer cell lines (Fig. 3).
CONCLUSIONS
This research aimed and proved that Micro or Nano prolipo-
some tablets could be effectively used to deliver PTX loaded
into liposomes into the TSI via Vibrating mesh (i.e. Omron)
and Ultrasonic nebulizers. From the initial characterization
(i.e. angle of repose, entrapment efficiency and size analysis)
LMH-based proliposome powder formulations (i.e. F3, F6
and F9) were found better especially in 1:25 w/w ratios (re-
gardless of phospholipid type). These three Micro formula-
tions were also probe sonicated in order to reduce the size to
Nano liposome, followed by spray drying (i.e. F3SDN,
F6SDN, F9SDN and F24SDN). Nano proliposome powder
formulations showed good production yield with poor to very
poor compressibility index values. However, amongMicro and
Nano proliposome tablets formulations (F3, F6, F9, F3SDN,
F6SDN and F9SDN), formulation F3 exhibited uniform
weight uniformity, high crushing strength, good tablet thick-
ness and short disintegration time. Moreover, nebulization of
liposome generated from PTX-loaded Micro proliposome
tablets (F3 formulation) demonstrated a better aerosolization
characteristics via Ultrasonic nebulizer as compared to
Vibrating mesh nebulizer in terms of short nebulization time
and high output rate. Thus, it was identified that PTX-loaded
Micro proliposome tablets manufactured using LMH as a
carrier in a 1:25 w/w lipid phase to carrier ratio are appro-
priate for the delivery of hydrophobic drug. Cytotoxicity stud-
ies demonstrated that proliposome tablet formulations F3 was
entirely safe in normal cell lines while toxic to cancer cell lines.
This is the first study that demonstrated the possibility of man-
ufacturing anticancer proliposome tablets that can disinte-
grate in aqueous medium and generate inhalable anticancer
liposomes via nebulization. Furthermore, evidence on the
cytotoxicity of the anticancer formulation on the cancerous
cell were also provided identifying its effectiveness.
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